These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

401 related articles for article (PubMed ID: 34343033)

  • 1. Avapritinib Versus Regorafenib in Locally Advanced Unresectable or Metastatic GI Stromal Tumor: A Randomized, Open-Label Phase III Study.
    Kang YK; George S; Jones RL; Rutkowski P; Shen L; Mir O; Patel S; Zhou Y; von Mehren M; Hohenberger P; Villalobos V; Brahmi M; Tap WD; Trent J; Pantaleo MA; Schöffski P; He K; Hew P; Newberry K; Roche M; Heinrich MC; Bauer S
    J Clin Oncol; 2021 Oct; 39(28):3128-3139. PubMed ID: 34343033
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Avapritinib in unresectable or metastatic PDGFRA D842V-mutant gastrointestinal stromal tumours: Long-term efficacy and safety data from the NAVIGATOR phase I trial.
    Jones RL; Serrano C; von Mehren M; George S; Heinrich MC; Kang YK; Schöffski P; Cassier PA; Mir O; Chawla SP; Eskens FALM; Rutkowski P; Tap WD; Zhou T; Roche M; Bauer S
    Eur J Cancer; 2021 Mar; 145():132-142. PubMed ID: 33465704
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical efficacy comparison of avapritinib with other tyrosine kinase inhibitors in gastrointestinal stromal tumors with PDGFRA D842V mutation: a retrospective analysis of clinical trial and real-world data.
    von Mehren M; Heinrich MC; Shi H; Iannazzo S; Mankoski R; Dimitrijević S; Hoehn G; Chiroli S; George S
    BMC Cancer; 2021 Mar; 21(1):291. PubMed ID: 33740926
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Avapritinib in advanced PDGFRA D842V-mutant gastrointestinal stromal tumour (NAVIGATOR): a multicentre, open-label, phase 1 trial.
    Heinrich MC; Jones RL; von Mehren M; Schöffski P; Serrano C; Kang YK; Cassier PA; Mir O; Eskens F; Tap WD; Rutkowski P; Chawla SP; Trent J; Tugnait M; Evans EK; Lauz T; Zhou T; Roche M; Wolf BB; Bauer S; George S
    Lancet Oncol; 2020 Jul; 21(7):935-946. PubMed ID: 32615108
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term follow-up results of the multicenter phase II trial of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of standard tyrosine kinase inhibitor therapy.
    Ben-Ami E; Barysauskas CM; von Mehren M; Heinrich MC; Corless CL; Butrynski JE; Morgan JA; Wagner AJ; Choy E; Yap JT; Van den Abbeele AD; Solomon SM; Fletcher JA; Demetri GD; George S
    Ann Oncol; 2016 Sep; 27(9):1794-9. PubMed ID: 27371698
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Circulating tumor DNA analysis of the phase III VOYAGER trial: KIT mutational landscape and outcomes in patients with advanced gastrointestinal stromal tumor treated with avapritinib or regorafenib.
    Serrano C; Bauer S; Gómez-Peregrina D; Kang YK; Jones RL; Rutkowski P; Mir O; Heinrich MC; Tap WD; Newberry K; Grassian A; Shi H; Bialick S; Schöffski P; Pantaleo MA; von Mehren M; Trent JC; George S
    Ann Oncol; 2023 Jul; 34(7):615-625. PubMed ID: 37105265
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase II trial of regorafenib in patients with metastatic and/or a unresectable gastrointestinal stromal tumor harboring secondary mutations of exon 17.
    Yeh CN; Chen MH; Chen YY; Yang CY; Yen CC; Tzen CY; Chen LT; Chen JS
    Oncotarget; 2017 Jul; 8(27):44121-44130. PubMed ID: 28487491
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial.
    Demetri GD; Reichardt P; Kang YK; Blay JY; Rutkowski P; Gelderblom H; Hohenberger P; Leahy M; von Mehren M; Joensuu H; Badalamenti G; Blackstein M; Le Cesne A; Schöffski P; Maki RG; Bauer S; Nguyen BB; Xu J; Nishida T; Chung J; Kappeler C; Kuss I; Laurent D; Casali PG;
    Lancet; 2013 Jan; 381(9863):295-302. PubMed ID: 23177515
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Avapritinib in Patients With Advanced Gastrointestinal Stromal Tumors Following at Least Three Prior Lines of Therapy.
    George S; Jones RL; Bauer S; Kang YK; Schöffski P; Eskens F; Mir O; Cassier PA; Serrano C; Tap WD; Trent J; Rutkowski P; Patel S; Chawla SP; Meiri E; Gordon M; Zhou T; Roche M; Heinrich MC; von Mehren M
    Oncologist; 2021 Apr; 26(4):e639-e649. PubMed ID: 33453089
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Financial Implications of Avapritinib for Treatment of Unresectable Gastrointestinal Stromal Tumors in Patients With a PDGFRA Exon 18 Variant or After 3 Previous Therapies in a Hypothetical US Health Plan.
    Proudman D; Miller A; Nellesen D; Gomes A; Mankoski R; Norregaard C; Sullivan E
    JAMA Netw Open; 2020 Nov; 3(11):e2025866. PubMed ID: 33201235
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and Safety of Avapritinib in Treating Unresectable or Metastatic Gastrointestinal Stromal Tumors: A Phase I/II, Open-Label, Multicenter Study.
    Li J; Zhang X; Deng Y; Wu X; Zheng Z; Zhou Y; Cai S; Zhang Y; Zhang J; Tao K; Cui Y; Cao H; Shen K; Yu J; Zhou Y; Ren W; Qu C; Zhao W; Hu J; Wang W; Yang J; Shen L
    Oncologist; 2023 Feb; 28(2):187-e114. PubMed ID: 36477870
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tyrosine kinase inhibitors in the treatment of unresectable or metastatic gastrointestinal stromal tumors.
    Nishida T; Doi T; Naito Y
    Expert Opin Pharmacother; 2014 Oct; 15(14):1979-89. PubMed ID: 24990162
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimal Avapritinib Treatment Strategies for Patients with Metastatic or Unresectable Gastrointestinal Stromal Tumors.
    Joseph CP; Abaricia SN; Angelis MA; Polson K; Jones RL; Kang YK; Riedel RF; Schöffski P; Serrano C; Trent J; Tetzlaff ED; Si TD; Zhou T; Doyle A; Bauer S; Roche M; Havnaer T
    Oncologist; 2021 Apr; 26(4):e622-e631. PubMed ID: 33301227
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Clinicopathological features and prognosis of gastrointestinal stromal tumors with
    Shen YY; Li XQ; Yang LX; Fang Y; Nie MM; He ZR; Hou YY; Cao H; Wang M; Shen KT
    Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Sep; 24(9):804-813. PubMed ID: 34530562
    [No Abstract]   [Full Text] [Related]  

  • 15. Efficacy and safety of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of imatinib and sunitinib: a multicenter phase II trial.
    George S; Wang Q; Heinrich MC; Corless CL; Zhu M; Butrynski JE; Morgan JA; Wagner AJ; Choy E; Tap WD; Yap JT; Van den Abbeele AD; Manola JB; Solomon SM; Fletcher JA; von Mehren M; Demetri GD
    J Clin Oncol; 2012 Jul; 30(19):2401-7. PubMed ID: 22614970
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Survival of advanced/recurrent gastrointestinal stromal tumors treated with tyrosine kinase inhibitors in Taiwan: a nationwide registry study.
    Tsai HJ; Shan YS; Yang CY; Hsiao CF; Tsai CH; Wang CC; Lin MT; Ting CF; Chan DC; Chen TH; Yen CC; Chen YY; Lin HY; Yeh TS; Ho CL; Shieh TY; Bai LY; Hsu JT; Chen IS; Chen LT; Yeh CN;
    BMC Cancer; 2024 Jul; 24(1):828. PubMed ID: 38992597
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Avapritinib in the treatment of PDGFRA exon 18 mutated gastrointestinal stromal tumors.
    Smrke A; Gennatas S; Huang P; Jones RL
    Future Oncol; 2020 Aug; 16(22):1639-1646. PubMed ID: 32517495
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of Wee1 as a target in combination with avapritinib for gastrointestinal stromal tumor treatment.
    Ye S; Sharipova D; Kozinova M; Klug L; D'Souza J; Belinsky MG; Johnson KJ; Einarson MB; Devarajan K; Zhou Y; Litwin S; Heinrich MC; DeMatteo R; von Mehren M; Duncan JS; Rink L
    JCI Insight; 2021 Jan; 6(2):. PubMed ID: 33320833
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Robust Activity of Avapritinib, Potent and Highly Selective Inhibitor of Mutated KIT, in Patient-derived Xenograft Models of Gastrointestinal Stromal Tumors.
    Gebreyohannes YK; Wozniak A; Zhai ME; Wellens J; Cornillie J; Vanleeuw U; Evans E; Gardino AK; Lengauer C; Debiec-Rychter M; Sciot R; Schöffski P
    Clin Cancer Res; 2019 Jan; 25(2):609-618. PubMed ID: 30274985
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Avapritinib (Ayvakit) for GIST.
    Med Lett Drugs Ther; 2021 Feb; 63(1617):23-24. PubMed ID: 33647006
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 21.